MALIGNANT HEMANGIOENDOTHELIOMA

HAZUKI IHDA, YOSHIKI TOKURA, MISAO FUSHIMI, RYUICHI YOKOTE, HIDEO HASHIZUME, SHIGEHO SHIRAHAMA, KEIJI IWATSUKI, KYOKO MURAKAMI, MASAHIRO TAKIGAWA

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

Background. The administration of interleukin‐2 (il‐2) has recently been reported to be favorable for treating malignant hemangioendothelioma (mhe). Methods. Two patients with mhe responded well to intra‐lesional injections of recombinant il‐2 (ril‐2) without major side effects. The purpose of this study was to characterize cells infiltrating the regressing tumor following ril‐2 treatment. Immunohistochemical studies were performed on biopsy specimens taken from ril‐2‐injected lesional skin. Results. It was shown that CD8+ lymphocytes and CD56+ natural killer (nk) cells infiltrated at the ril‐2‐injection sites, suggesting that these cells contributed to the tumor regression. In addition, MHE cells bore intercellular adhesion mole‐cule‐1 (icam‐1) whose expression was augmented by rn‐2 injections. Conclusions. These findings suggested, that ril‐2 not only induces lymphokine‐activated killer (lak) cells and nk cells, but also facilitates these cytotoxic cells to adhere to MHE cells by enhancing icam‐1 expression of tumor cells.

Original languageEnglish
Pages (from-to)811-816
Number of pages6
JournalInternational Journal of Dermatology
Volume34
Issue number11
DOIs
Publication statusPublished - Nov 1995

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'MALIGNANT HEMANGIOENDOTHELIOMA'. Together they form a unique fingerprint.

Cite this